11 completed, 3 unknown, 1 active not recruiting, 1 recruiting. 8 Phase 3, 7 Phase 2, 6 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 8 | Completed 5, Unknown 2, Recruiting 1 |
| Phase 2 | 7 | Completed 5, Active not recruiting 1, Unknown 1 |
| Phase 1 | 6 | Completed 4, Active not recruiting 1, Unknown 1 |
Follow SK Bioscience Co., Ltd.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SkyVaricella® (NBP608) Vaccine With Lower Potencies in Healthy Children Aged 12 Months to 12 Years NBP608 (Mid Potency), NBP608 (Low Potency), Varivax® - Varicella (Chickenpox) | Phase 3 | Recruiting | SK Bioscience Co., Ltd. | 780 | 2026-07-04 | 2026-09-15 |
| A Phase I/II, Dose-finding Study to Assess the Safety, Reactogenicity, and Immunogenicity of a Broadly Protective Sarbecovirus Vaccine (GBP511) in Healthy Adults. Test Drug 1-1 (GBP511 low dose), Test Drug 1-2 (GBP511 mid dose), Test Drug 1-3 (GBP511 high dose) - Healthy Participants, Sarbecovirus | Phase 1 / Phase 2 | Active not recruiting | SK Bioscience Co., Ltd. | 368 | 2026-01-28 | 2026-09-09 |
| A Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis Messenger Ribonucleic Acid (mRNA) Vaccines (GBP560) in Healthy Adults GBP560-A, GBP560-B, IXIARO - Japanese Encephalitis Virus Disease | Phase 1 / Phase 2 | Completed | SK Bioscience Co., Ltd. | 161 | 2025-02-24 | 2026-09-11 |
| A Blood Collection Study to Assess the Immunogenicity of Nationally Authorized Homologous COVID-19 Booster Vaccines Among Adult Vaccinees. Immune Responses - COVID-19 | Withdrawn | SK Bioscience Co., Ltd. | 2023-02-01 | 2023-07-27 | ||
| Immunogenicity and Safety Study of Heterologous Booster Vaccination of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine(GBP510) Adjuvanted with AS03 in Adults Aged 18 Years and Older GBP510 adjuvanted with AS03, Placebo (Normal Saline) - COVID-19 | Phase 3 | Completed | SK Bioscience Co., Ltd. | 840 | 2022-12-09 | 2024-10-16 |
| Immunogenicity and Safety Study of SK SARS-CoV-2 Recombinant Nanoparticle Vaccine (GBP510) Adjuvanted With AS03 (COVID-19) GBP510 adjuvanted with AS03 (Receptor-Binding Domain(RBD) 25ug/dose), ChAdOx1-S not less than 2.5 × 10^8 infectious units - Covid19 | Phase 3 | Completed | SK Bioscience Co., Ltd. | 4036 | 2021-08-30 | 2024-04-08 |
| Mixed Schedule Study of Live Oral Rotavirus Vaccines and Trivalent P2-VP8 Subunit Rotavirus Vaccine RV3-BB, Trivalent P2-VP8, Rotarix - Rotavirus Vaccine | Phase 2 | Completed | PATH | 850 | 2021-02-22 | 2022-11-29 |
| Safety and Immunogenicity Study of SARS-CoV-2 Nanoparticle Vaccine (GBP510) Adjuvanted With or Without AS03 (COVID-19) GBP510 adjuvanted with AS03 (RBD 10μg/dose) - Stage 1, GBP510 (RBD 10μg/dose) - Stage 1, Normal saline (0.9% sodium chloride solution) - Stage 1 - COVID-19 (Healthy Volunteers) | Phase 1 / Phase 2 | Unknown | SK Bioscience Co., Ltd. | 328 | 2021-02-03 | 2022-05-10 |
| Safety and Immunogenicity Study of SARS-CoV-2 Nanoparticle Vaccine (GBP510) Adjuvanted With Aluminum Hydroxide (COVID-19) GBP510 adjuvanted with Alum (RBD 10μg/dose) - Stage 1, Normal saline (0.9% sodium chloride solution) - Stage 1, GBP510 adjuvanted with Alum (RBD 25μg/dose) - Stage 1 - COVID-19 (Healthy Volunteers) | Phase 1 / Phase 2 | Completed | SK Bioscience Co., Ltd. | 260 | 2021-01-20 | 2023-04-18 |
| Safety and Immunogenicity of a SARS-CoV-2 Vaccine (NBP2001) in Healthy Adults (COVID-19) NBP2001 adjuvanted with alum (RBD 30μg/dose), NBP2001 adjuvanted with alum (RBD 50μg/dose), Normal Saline - COVID-19 (Healthy Volunteers) | Phase 1 | Completed | SK Bioscience Co., Ltd. | 50 | 2020-12-17 | 2023-04-18 |
| Immune Equivalence Between Multi-dose and Single Dose Formulation of Vi-DT and Their Overall Safety (Phase III) Vi-DT (Multi-dose formulation), Vi-DT (Single dose formulation), Control Vaccine - Typhoid | Phase 3 | Completed | International Vaccine Institute | 1800 | 2020-02-04 | 2021-08-27 |
| Immune Non-inferiority and Safety of a Vi-DT Typhoid Conjugate Vaccine Test Vaccine Vi-DT Typhoid conjugate, Control Vaccine Typbar TCV® - Typhoid | Phase 3 | Unknown | International Vaccine Institute | 1800 | 2019-11-15 | 2020-04-22 |
| A Trial to Assess the Safety, Immunogenicity and Efficacy of a Trivalent Rotavirus P2-VP8 Subunit Vaccine in Prevention of Severe Rotavirus Gastroenteritis in Healthy Infants in Africa and India TV P2-VP8, Rotarix - Rotavirus Infection of Children | Phase 3 | Unknown | PATH | 8200 | 2019-10-10 | 2021-04-09 |
| Immunogenicity and Safety Study of NBP615 in Healthy Female NBP615, Gardasil - Cervical Cancer | Phase 1 / Phase 2 | Completed | SK Bioscience Co., Ltd. | 200 | 2018-12-22 | 2021-10-01 |
| Immunogenicity and Safety of NBP607-QIV Compared to Agrippal in Children Aged 6 to 35 Months NBP607-QIV, Agrippal - Influenza | Phase 3 | Completed | SK Bioscience Co., Ltd. | 676 | 2018-10-25 | 2022-05-11 |
| Safety, Reactogenicity and Immunogenicity of Vi-DT;Typhoid Conjugate Vaccine Vi-DT, FluQuadri™, 0.9% sodium chloride isotonic solution - Typhoid | Phase 2 | Completed | International Vaccine Institute | 285 | 2018-04-18 | 2021-08-27 |
| Immunogenicity and Safety of NBP608 Compared to Varivax in Healthy Children 12 Months to 12 Years of Age NBP608, Varivax - Varicella | Phase 3 | Completed | SK Bioscience Co., Ltd. | 516 | 2016-07-14 | 2019-05-08 |
COVID-19 (6) · Typhoid Fever (3) · Chickenpox (2) · Encephalitis, Japanese (1) · Influenza, Human (1) · Uterine Cervical Neoplasms (1)
Saline Solution (7) · Chickenpox Vaccine (2) · RIX4414 vaccine (2) · Sodium Chloride (2) · aluminum sulfate (2) · BNT162 Vaccine (1) · Diphtheria Toxoid (1) · Dosage Forms (1) · GBP510 vaccine (1) · Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 (1) · Immunity (1)
South Korea (7) · Philippines (5) · Australia (2) · Nepal (2) · New Zealand (2) · Thailand (2) · Colombia (1) · Honduras (1) · South Africa (1) · Ukraine (1) · Vietnam (1) · Zambia (1)
Hee Jin Cheong (3) · Santa K Das, MD (2) · Desiree Witte, MD (1) · Ganesh Kumar Rai, MD (1) · George Armah, PhD (1) · Josefina C Carlos, MD (1) · Maria Rosario Capeding, MD (1) · Myoung-Don Oh (1) · Roma Chilengi, MD (1) · Stanley Cryz, PhD (1) · Yun Kyung Kim, MD (1)
PMID 33873199, PMID 31585725, PMID 33150320, PMID 34942090, PMID 35664443, PMID 35879941, PMID 35988541, PMID 37711219, PMID 40446606, PMID 41319434